Source study found
Story checked
Cancer drug pushes mutant blood stem cells to become short-lived immune cells (opens in a new tab)
medicalxpress.com · 2026-09-15
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Cancer drug pushes mutant blood stem cells to become short-lived immune cells
medicalxpress.com · 2026-09-15
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Type 1 interferon perturbates clonal competition by reshaping human blood development
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedA study by Weill Cornell Medicine investigators found that the biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 8Not checkedBecause interferon-alpha can cause significant side effects, the authors say more focused strategies based on the mechanistic findings could meet an important need in cancer therapy.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 8Not checkedThe investigators used advanced single-cell profiling tools to discover how interferon-alpha exerts its effects, and the study was published in Nature Genetics.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 8Not checkedThe team sampled consenting patients with essential thrombocythemia, compared blood cells before and after interferon-alpha treatment, and examined how mutant and nonmutant blood cells responded differently.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 8Not checkedThe article says interferon-alpha can trigger an emergency infection-like response that pushes blood stem cells to mature rapidly into neutrophils, which do not live very long and therefore deplete blood stem cells over time.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 6 of 8Not checkedThe story says mutant blood stem cells are more susceptible to this process than nonmutant blood stem cells in patients who respond to interferon-alpha treatment.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 7 of 8Not checkedThe researchers also found that interferon-alpha treatment induces many blood stem cells to produce lymphoid cells and suppresses inflammaging-related gene programs.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 8 of 8Not checkedThe article says the findings suggest more selective and potent ways to reduce mutant blood cells in myeloproliferative neoplasms and possibly other blood cancers, and perhaps even precancerous conditions.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Type 1 interferon perturbates clonal competition by reshaping human blood development
Nature Genetics · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, Europe PMC, PubMed · 40 candidate papers
Type 1 interferon perturbates clonal competition by reshaping human blood development
Nature Genetics · 2026 · Crossref
Author Correction: Forensic genetics in the omics era
Nature Reviews Genetics · 2026 · Crossref
CytoSignal detects locations and dynamics of ligand-receptor signaling at cellular resolution from spatial transcriptomic data.
2026 · Europe PMC
Author response for "Synthesis of mesoionic carbene-triazole based Pd(II) complex: promoting C-H activation toward N-aryl carbazoles"
2026 · Crossref
RNU4ATAC-opathy: Clinical, molecular, and transcriptomic insights from a large cohort.
2026 · Europe PMC
Molecular characterization of mismatch repair deficient tumors in young Jordanian patients.
2026 · Europe PMC
And 34 more candidates considered.